Sanofi

The agency’s decision came after researchers found cases of drug-induced liver injury in some patients.

Monkeypox, test tubes

The continent has no vaccines for monkeypox and test kits are in short supply, international health agencies said on Thursday, warning that richer countries already appeared to be hoarding vaccines.

Pfizer BioNTech

Pfizer Inc. and partner BioNTech SE said on Wednesday they signed a $3.2 billion deal with the U.S. government for 105 million doses of their COVID-19 vaccine, which could be delivered as soon as later this summer.

Remote patient monitoring

Providers continue to adapt to the new care models to patients’ needs. As the pandemic wreaked havoc across the United States, healthcare providers started deploying various health IT solutions to address emerging challenges. They aimed to reduce the load on doctors and protect clinicians and patients from the virus exposure.

Paxlovid

Pfizer said it submitted a New Drug Application for Paxlovid to the FDA for the treatment of COVID-19 in vaccinated and unvaccinated people at high risk for progression to severe illness.

AstraZeneca

AstraZeneca said on Thursday a combination of its cancer drug, Imfinzi, and chemotherapy showed promise in a late-stage trial in patients with an aggressive form of lung cancer, when given before surgery.

Accord BioPharma, Eversana

CAMCEVI is the first-ever ready-to-inject sterile formulation of leuprolide for subcutaneous injection that comes in a pre-filled syringe with no mixing required. Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, Ltd., is heading distribution in the United States.

Initial results from Jazz Pharmaceuticals’ Phase III study on Sativex (JZP378) for the treatment of multiple sclerosis failed to achieve the primary endpoint of an improvement in muscle tone.

The World Health Organization says “sustained transmission” of monkeypox worldwide could see the virus begin to move into high-risk groups, such as pregnant women, immunocompromised people and children.

Pfizer BioNTech

Germany’s BioNTech, Pfizer’s partner in COVID-19 vaccines, said the two companies would start tests on humans of next-generation shots that protect against a wide variety of coronaviruses in the second half of the year.